Currently, Parkinson’s Disease is treated with deep brain stimulation surgical procedures and medications like Carbidopa-levodopa, Dopamine agonists, MAO B inhibitors, Catechol O-methyltransferase (COMT) inhibitors, Anticholinergics and Amantadine. Despite inducing temporary improvement, these approaches possess long-term adverse effects due to non-specific inhibition of neural responses. Additionally, current treatments do not address the issue of damage that has already occurred to the brain.
StemGenex is currently studying the effect of adult stem cell therapy on patients diagnosed with Parkinson’s Disease. Because the majority of complications in Parkinson’s patients are related to the failure of the dopamine neuron to do its job, stem cell therapy is being studied to directly target these neurons. The hope is that, by delivering adult stem cells directly to the brain they can differentiate into dopamine producing neurons resulting in diminished symptoms.